Don't' forget to compare ICO-007 to treatments mentioned in the previous article. Data form ICO's phase I study (http://www.icotherapeutics.com/_resources/Retina_Society_2010_David_Boyer.pdf) showed that more than 20% of patients had visual acuity improvement by over 5 letters. These patients failed all previous treatments by different therapies. So all therapies that you read in the previous article laser, vegf, steroids were ineffective at treating ICO's phase I patients.
Think about that. If ICO was able to have a significant impact on 20% of DME patients that no other therapy could treat, imagine what the outcome of ICO's therapy will be on patients who were responsive to previous therapies. I think it is reasonable to expect vast improvements in visual acuity of ico-007 in comparison to Lucentis.